<DOC>
	<DOCNO>NCT02532764</DOCNO>
	<brief_summary>A randomized , double-blind , placebo-controlled study single multiple ascend dos QR-010 adult homozygous ΔF508 Cystic Fibrosis .</brief_summary>
	<brief_title>Dose Escalation Study QR-010 Homozygous ΔF508 Cystic Fibrosis Patients</brief_title>
	<detailed_description>The purpose study evaluate safety , tolerability , determine pharmacokinetics QR-010 administered via inhalation adult homozygous ΔF508 Cystic Fibrosis .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Confirmed diagnosis CF define iontophoretic pilocarpine sweat chloride test ( sweat chloride ) &gt; 60 mmol/L Confirmation CFTR gene mutation homozygous ΔF508 mutation Body mass index ( BMI ) ≥ 17 kg/m2 Nonsmoking minimum two year FEV1 ≥70 % predict normal age , gender , height , Screening Stable lung function Adequate hepatic renal function Breast‐feeding pregnant Use lumacaftor ivacaftor Use investigational drug device History lung transplantation Hemoptysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>cystic fibrosis</keyword>
	<keyword>ΔF508</keyword>
	<keyword>RNA therapy</keyword>
	<keyword>antisense oligonucleotide</keyword>
	<keyword>CFTR</keyword>
	<keyword>F508del</keyword>
	<keyword>CF</keyword>
	<keyword>RNA therapy</keyword>
</DOC>